Literature DB >> 1905049

Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988.

D P Rice1, S Kelman, L S Miller.   

Abstract

The high prevalence of alcohol and drug abuse and mental illness imposes a substantial financial burden on those affected and on society. The authors present estimates of the economic costs from these causes for 1985 and 1988, based on current and reliable data available from national surveys and the use of new costing methodology. The total losses to the economy related to alcohol and drug abuse and mental illness for 1988 are estimated at $273.3 billion. The estimate includes $85.8 billion for alcohol abuse, $58.3 billion for drug abuse, and $129.3 billion for mental illness. The total estimated costs for 1985, $218.1 billion, include $51.4 billion for direct treatment and support costs; $80.8 billion for morbidity costs, the value of reduced or lost productivity; $35.8 billion for mortality costs, the value of foregone future productivity for the 140,593 premature deaths associated with these disorders, based on a 6 percent discount rate and including an imputed value for housekeeping services; and $47.5 billion in other related costs, including the costs of crime, motor vehicle crashes, fire destruction, and the value of productivity losses for victims of crime, incarceration, crime careers, and caregiver services. The cost of acquired immunodeficiency syndrome associated with drug abuse is estimated at $1 billion, and the cost of fetal alcohol syndrome is estimated at $1.6 billion. The estimates may be considered lower limits of the true costs to society of alcohol and drug abuse and mental illness in the United States.

Entities:  

Mesh:

Year:  1991        PMID: 1905049      PMCID: PMC1580246     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  11 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  US medical school finances.

Authors:  P Jolly; L Taksel; D Baime
Journal:  JAMA       Date:  1986-09-26       Impact factor: 56.272

3.  Cost model for baccalaureate nursing education.

Authors:  K Kummer; G Bednash; B Redman
Journal:  J Prof Nurs       Date:  1987 May-Jun       Impact factor: 2.104

4.  Associations among major psychiatric diagnoses.

Authors:  A W Wolf; D S Schubert; M B Patterson; T P Grande; K J Brocco; L Pendleton
Journal:  J Consult Clin Psychol       Date:  1988-04

5.  The economic cost of illness revisited.

Authors:  B S Cooper; D P Rice
Journal:  Soc Secur Bull       Date:  1976-02

6.  Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

Authors:  A A Scitovsky; D P Rice
Journal:  Public Health Rep       Date:  1987 Jan-Feb       Impact factor: 2.792

7.  One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

Authors:  D A Regier; J H Boyd; J D Burke; D S Rae; J K Myers; M Kramer; L N Robins; L K George; M Karno; B Z Locke
Journal:  Arch Gen Psychiatry       Date:  1988-11

Review 8.  Incidence of fetal alcohol syndrome and economic impact of FAS-related anomalies.

Authors:  E L Abel; R J Sokol
Journal:  Drug Alcohol Depend       Date:  1987-01       Impact factor: 4.492

9.  Drinking patterns and drinking problems in 1984: results from a general population survey.

Authors:  M E Hilton
Journal:  Alcohol Clin Exp Res       Date:  1987-04       Impact factor: 3.455

10.  The economic costs of illness: a replication and update.

Authors:  D P Rice; T A Hodgson; A N Kopstein
Journal:  Health Care Financ Rev       Date:  1985
View more
  27 in total

Review 1.  The cost-effectiveness of substance abuse treatment.

Authors:  P G Barnett
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

2.  Health care utilization among drug-using and non-drug-using women.

Authors:  Claire E Sterk; Katherine P Theall; Kirk W Elifson
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

3.  Substance abuse treatment as HIV prevention: more questions than answers.

Authors:  Lawrence S Brown; Steven Kritz; Edmund J Bini; Ben Louie; Jim Robinson; Donald Alderson; John Rotrosen
Journal:  J Natl Med Assoc       Date:  2010-12       Impact factor: 1.798

4.  Substance use, mental illness and violence: the co-occurrence of problem behaviors among young adults.

Authors:  Richard A Van Dorn; James Herbert Williams; Melissa Del-Colle; J David Hawkins
Journal:  J Behav Health Serv Res       Date:  2008-12-17       Impact factor: 1.505

Review 5.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

6.  Course of major depressive disorder and labor market outcome disruption.

Authors:  Zhehui Luo; Alexander J Cowell; Yuta J Musuda; Scott P Novak; Eric O Johnson
Journal:  J Ment Health Policy Econ       Date:  2010-09

Review 7.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

8.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

9.  Redefining the goals of national drug policy: recommendations from a working group.

Authors:  P Reuter; J P Caulkins
Journal:  Am J Public Health       Date:  1995-08       Impact factor: 9.308

10.  Quantifying the disease impact of alcohol with ARDI software.

Authors:  J M Shultz; D P Rice; D L Parker; R A Goodman; G Stroh; N Chalmers
Journal:  Public Health Rep       Date:  1991 Jul-Aug       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.